---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| 2Q26 | Second quarter of 2026 |
| 4Q | Fourth quarter |
| A-005 | Alumis development code for a central nervous system penetrant allosteric TYK2 inhibitor |
| AAD | American Academy of Dermatology |
| AAD-NPF | American Academy of Dermatology and National Psoriasis Foundation (joint guidelines) |
| AAPC | Average annual percent change |
| ACD | Adjusted cost difference |
| AD | Atopic dermatitis |
| ADA | Adalimumab |
| ADRs | Adverse drug reactions |
| AE, AEs | Adverse event; adverse effect |
| AHFS | American Hospital Formulary Service |
| aHR, aHRs | Adjusted hazard ratio |
| aIRR | Adjusted incidence rate ratio |
| ALP | Alkaline phosphatase |
| ALT | Alanine aminotransferase |
| ANOVA | Analysis of variance |
| anti-HBc | Antibody to hepatitis B core antigen |
| anti-HBs | Antibody to hepatitis B surface antigen |
| ANZCTR | Australian New Zealand Clinical Trials Registry |
| aOR | Adjusted odds ratio |
| APAC | Asia-Pacific |
| API | Active pharmaceutical ingredient; application programming interface |
| ASIR | Age-standardized incidence rate |
| ASP | Average sales price |
| ASR, ASRs | Age-standardized rate |
| AST | Aspartate aminotransferase |
| ATM | At-the-market (equity offering) |
| ATP | Adenosine triphosphate |
| AUC | Area under the concentration-time curve |
| AUC(0-τ), AUC0-τ, AUC0–tau, AUCtau | Area under the concentration-time curve over the dosing interval |
| AUC(INF), AUC0–inf | Area under the concentration-time curve from time zero extrapolated to infinite time |
| AUC0-τ,ss | Area under the concentration-time curve for the dosing interval at steady state |
| AUC0–t, AUCt | Area under the concentration-time curve from time zero to the last measurable concentration |
| BAD | British Association of Dermatologists |
| BID | Twice daily |
| BIW | Twice weekly |
| BMI | Body mass index |
| BMS | Bristol Myers Squibb |
| BMT-153261 | Code for the active metabolite of deucravacitinib |
| BP | Blood pressure |
| BSA | Body surface area |
| BWAUC, BWAUC0-τ | Body weight normalized area under the concentration-time curve |
| BWCmax | Body weight normalized maximum plasma concentration |
| CCL19 | C-C motif chemokine ligand 19 |
| CCR7 | C-C motif chemokine receptor 7 |
| CES | Carboxylesterase |
| CI, CIs | Confidence interval |
| CKD | Chronic kidney disease |
| CL/F | Apparent clearance |
| CLr | Renal clearance of unchanged drug from the plasma |
| Cmax | Maximum observed plasma concentration |
| Cmax,ss | Maximum plasma concentration at steady state |
| CMS | Centers for Medicare & Medicaid Services |
| CNS | Central nervous system |
| COPD | Chronic obstructive pulmonary disease |
| COVID-19, COVID | Coronavirus disease 2019 |
| CPK | Creatine phosphokinase |
| CPR, CPRs | Cost per response |
| CPT | Current Procedural Terminology |
| CrCl | Creatinine clearance |
| CrI | Credible interval |
| CRO | Clinical research organization |
| CRU | Clinical research unit |
| Ctrough | Trough plasma concentration (concentration immediately before the next dose) |
| CV, CV% | Cardiovascular; coefficient of variation |
| CXCL1, CXCL2, CXCL3, CXCL5, CXCL8, CXCL10 | C-X-C motif chemokine ligand 1, 2, 3, 5, 8, and 10 |
| CY | Calendar year |
| CYP, CYP450, P450 | Cytochrome P450 |
| DDI | Drug-drug interaction |
| DEU | Deucravacitinib |
| DLQI | Dermatology Life Quality Index |
| DLQI 0/1, DLQI-0/1, DLQI0/1 | Dermatology Life Quality Index score of 0 or 1 |
| DSHS | Department of State Health Services (Texas) |
| E-R | Exposure-response |
| EAIR, EAIRs | Exposure-adjusted incidence rate |
| ECG, ECGs | Electrocardiogram |
| eCRF | Electronic case report form |
| ED | Erectile dysfunction |
| EE | Expert elicitation |
| EEA | European Economic Area |
| EF | Efficiency frontier |
| eGFR | Estimated glomerular filtration rate |
| EHR | Electronic health record |
| EMA | European Medicines Agency |
| envu | Envudeucitinib (manufacturer shorthand) |
| EQ-5D, EQ-5D-3L, EQ-5D-5L | EuroQol 5-Dimension questionnaire (3-level and 5-level versions) |
| EQ-VAS | EuroQol visual analogue scale |
| ER | Emergency room |
| ERAP1 | Endoplasmic reticulum aminopeptidase 1 |
| ESK-001, ESK001, ESK 001 | Alumis development code for envudeucitinib |
| EU | European Union |
| EU5 | France, Germany, Spain, the U.K., and Italy |
| EudraCT | European Union Drug Regulating Authorities Clinical Trials Database |
| FDA | U.S. Food and Drug Administration |
| FDLQI | Family Dermatology Life Quality Index |
| %Fe | Percentage of unchanged drug excreted |
| FE | Food effect |
| FSH | Follicle-stimulating hormone |
| FSS | Federal Supply Schedule |
| FTP-637 | FronThera development code for envudeucitinib |
| GBD | Global Burden of Disease (study) |
| GGT | Gamma glutamyl transferase |
| GI | Gastrointestinal |
| GQ | Global question |
| H2 | Histamine-2 (receptor) |
| HBsAg | Hepatitis B surface antigen |
| HBV | Hepatitis B virus |
| HCAI | Department of Health Care Access and Information (California) |
| HCPCS | Healthcare Common Procedure Coding System |
| HCPro | HUMIRA Complete Pro (online prescription management system) |
| HCRU | Healthcare resource utilization |
| HCV | Hepatitis C virus |
| HEDIS | Healthcare Effectiveness Data and Information Set |
| HERC5 | HECT and RLD domain containing E3 ubiquitin protein ligase 5 |
| hERG | Human ether-a-go-go-related gene |
| HIV, HIV-1, HIV-2 | Human immunodeficiency virus (types 1 and 2) |
| HLA-C | Human leukocyte antigen C |
| HMO | Health maintenance organization |
| HR | Hazard ratio; heart rate; hour (in a product description) |
| HRQOL, HRQoL, HrQOL | Health-related quality of life |
| HWB | Human whole blood |
| IBD | Inflammatory bowel disease |
| IC50 | 50% inhibitory concentration |
| IC90 | 90% inhibitory concentration |
| ICC, ICCs | Intraclass correlation coefficient |
| ICD, ICD-10, ICD-10-CM, ICD-9-CM | International Classification of Diseases (10th revision; 10th and 9th revisions, Clinical Modification) |
| ICER | Institute for Clinical and Economic Review; incremental cost-effectiveness ratio |
| ICF | Informed consent form |
| ICH | International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use |
| ID | Identifier |
| IFI27 | Interferon alpha inducible protein 27 |
| IFIH1 | Interferon induced with helicase C domain 1 |
| IFIT1 | Interferon induced protein with tetratricopeptide repeats 1 |
| IFN, IFNs | Interferon |
| IFNGS | Interferon gene signature |
| IFNα | Interferon alpha |
| IFNγ, IFNG | Interferon gamma |
| IGA | Investigator’s Global Assessment |
| IGRA | Interferon-gamma release assay |
| IL | Interleukin |
| IL12B | Interleukin 12B (gene) |
| IL23R | Interleukin 23 receptor (gene) |
| IL4I1 | Interleukin 4 induced 1 |
| IM | Intramuscular |
| INJ | Injection (in a product description) |
| INN | International Nonproprietary Name |
| IPC | International Psoriasis Council |
| IPD | Important protocol deviations |
| IQR | Interquartile range |
| IRAS | Integrated Research Application System |
| IRR, IRRs | Incidence rate ratio |
| ITT | Intent-to-treat (intention-to-treat) |
| IUD | Intrauterine device |
| IV | Intravenous |
| JAK, JAK1, JAK2, JAK3 | Janus kinase (1, 2, 3) |
| JAKi | Janus kinase inhibitors |
| JH1 | JAK homology 1 (catalytic kinase domain) |
| JH2 | JAK homology 2 (pseudokinase domain) |
| LCE3 | Late cornified envelope 3 |
| LOCF | Last observation carried forward |
| LS | Least squares |
| LSMs | Least squares means |
| LTE | Long-term extension |
| MACE | Major adverse cardiovascular events |
| MAD | Multiple ascending dose |
| %Max_AUCW16 | Percent maximum area under the response curve through week 16 |
| mBOCF | Modified baseline observation carried forward |
| MCDs | Mean cost differences |
| MD | Multiple-dose (study) |
| MFPs | Maximum fair prices |
| MHC | Major histocompatibility complex |
| MI | Myocardial infarction |
| MIPS | Merit-based Incentive Payment System |
| mITT | Modified intent-to-treat |
| MMF | Mycophenolate mofetil |
| MMRM | Mixed model with repeated measures |
| mNRI | Modified non-responder imputation |
| MR | Mendelian randomization |
| MRAUC | Metabolite to parent ratio based on area under the concentration-time curve |
| MRCmax | Metabolite to parent ratio based on maximum plasma concentration |
| mRNA | Messenger ribonucleic acid |
| MS | Multiple sclerosis |
| MSPP | Moderate-to-severe plaque psoriasis |
| MTX | Methotrexate |
| NAFLD | Nonalcoholic fatty liver disease |
| NB-UVB | Narrowband ultraviolet B |
| NCQA | National Committee for Quality Assurance |
| NDA | New Drug Application |
| NDC, NDCs, NDC11 | National Drug Code (11-digit format) |
| NF-kappa B | Nuclear factor kappa B |
| NHANES | National Health and Nutrition Examination Survey |
| NHIS | National Health Interview Survey |
| NMSC | Nonmelanoma skin cancer |
| NNT | Number needed to treat |
| NPF | National Psoriasis Foundation |
| NRI | Non-responder imputation |
| NRS | Numeric Rating Scale |
| NRW | North Rhine-Westphalia (in an address) |
| NYSE | New York Stock Exchange |
| OLE | Open-label extension |
| OR | Odds ratio |
| OSA | Obstructive sleep apnea |
| P-gp | P-glycoprotein |
| P-SIM | Psoriasis Symptoms and Impacts Measure |
| PA, PAs | Prior authorization |
| PASI | Psoriasis Area and Severity Index |
| PASI 50, PASI 75, PASI 90, PASI 100 (PASI-50, PASI-75, PASI75, PASI-90, PASI90, PASI-100) | Improvement from baseline in the Psoriasis Area and Severity Index of at least 50%, 75%, 90%, or 100% |
| PCT | Patent Cooperation Treaty |
| PD | Pharmacodynamics |
| PDE4 | Phosphodiesterase 4 |
| PDI | Psoriasis Disability Index |
| PDUFA | Prescription Drug User Fee Act |
| PEST | Psoriasis Epidemiology Screening Tool |
| PFIS | Patient Family Impact Score |
| PFS | Prefilled syringe (in a product description) |
| PGA | Physician’s Global Assessment |
| Ph1, Ph2 | Phase 1, phase 2 |
| PHQ-2 | Patient Health Questionnaire-2 |
| PI | Principal investigator |
| PK | Pharmacokinetics |
| PMPM | Per member per month |
| PP | Per-protocol |
| PPIs | Proton pump inhibitors |
| PPO | Preferred provider organization |
| PPPM | Per patient per month |
| PPPY | Per patient per year |
| PR | PR interval of the electrocardiogram (onset of the P wave to onset of the QRS complex) |
| Ps | Plaque psoriasis |
| PsA | Psoriatic arthritis |
| PsO, PSO | Psoriasis; plaque psoriasis |
| PsoRA | Psoriasis Registry Austria |
| PSQI | Pittsburgh Sleep Quality Index |
| PSSD | Psoriasis Symptoms and Signs Diary |
| pSTAT, pSTAT1 | Phosphorylated signal transducer and activator of transcription (1) |
| PT | Preferred term |
| PUVA | Psoralen plus ultraviolet A |
| PY | Patient-years; participant-years |
| Q1 | First quarter |
| Q12 | Every 12 hours |
| Q2W | Every 2 weeks |
| Q3 | Third quarter |
| QALY, QALYs | Quality-adjusted life year |
| QCDR | Qualified Clinical Data Registry |
| QD, q.d. | Once daily |
| QoL, QOL | Quality of life |
| QRS | QRS complex of the electrocardiogram (ventricular depolarization) |
| QT | QT interval of the electrocardiogram (onset of the QRS complex to end of the T wave) |
| QTc | QT interval corrected for heart rate |
| QTcF | QT interval corrected using Fridericia’s method |
| ∆∆QTcF | Change from baseline in placebo-adjusted QT interval corrected using Fridericia’s method |
| RA | Rheumatoid arthritis |
| RAC, Rac | Accumulation ratio |
| RCTs | Randomized controlled trials |
| REC | Research Ethics Committee |
| REMS | Risk Evaluation and Mitigation Strategy |
| RNA | Ribonucleic acid |
| RNA-seq | Ribonucleic acid sequencing |
| RNF113 | Ring finger protein 113 |
| ROW | Rest of world |
| RR, RRs | Relative risk (risk ratio) |
| RSAD2 | Radical S-adenosyl methionine domain containing 2 |
| RWP | Randomized withdrawal period |
| RZB | Risankizumab |
| SA | South Australia |
| SAD | Single ascending dose |
| SAE, SAEs | Serious adverse event |
| SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 |
| SC | Subcutaneous |
| SD | Standard deviation; sleep disturbance |
| SIGLEC1 | Sialic acid binding Ig like lectin 1 |
| SIR | Standard incidence rate |
| SLE | Systemic lupus erythematosus |
| SMC | Safety monitoring committee |
| SMD | Standardized mean difference |
| SMR | Standardized mortality ratio |
| SNP | Single nucleotide polymorphism |
| SOC | System organ class |
| sPGA | Static Physician’s Global Assessment |
| sPGA 0/1, sPGA-0/1 | Static Physician’s Global Assessment score of 0 (clear) or 1 (almost clear) |
| ss-PGA, ssPGA | Scalp-specific Physician’s Global Assessment |
| ss-PGA-0/1 | Scalp-specific Physician’s Global Assessment score of 0 (clear) or 1 (almost clear) |
| STAT, STAT1, STAT3, STAT4 | Signal transducer and activator of transcription (1, 3, 4) |
| Strep | Streptococcus |
| SUCRA | Surface under the cumulative ranking curve |
| t1/2, t½, t½λz | Elimination half-life |
| t1/2,ss | Terminal elimination half-life at steady state |
| TAB | Tablet (in a product description) |
| TAK-279 | Takeda development code for zasocitinib |
| TB | Tuberculosis |
| TEAE, TEAEs | Treatment-emergent adverse event |
| Th1 | T helper 1 |
| Th17 | T helper 17 |
| Tmax | Time of maximum plasma concentration |
| Tmax,ss | Time to reach maximum plasma concentration at steady state |
| TNF, TNFα, TNF-alpha | Tumor necrosis factor (alpha) |
| TNIP1 | TNFAIP3 interacting protein 1 |
| TPO | Thrombopoietin |
| TSE | Tokyo Stock Exchange |
| TYK2, TYK-2 | Tyrosine kinase 2 |
| TYK2i | TYK2 inhibition; TYK2 inhibitors |
| U.K., UK | United Kingdom |
| U.S., US | United States |
| UGT | Uridine glucuronyl transferase |
| ULN | Upper limit of normal |
| USA | United States of America |
| USAN | United States Adopted Name |
| USD | U.S. dollars |
| UV | Ultraviolet; uveitis |
| UVB, UV-B | Ultraviolet B |
| Vd/F | Apparent volume of distribution |
| VRS | Visual Rating Scale |
| Vss/F | Apparent steady-state volume of distribution |
| Vz/F | Apparent volume of distribution during the terminal phase |
| WAC, WACs | Wholesale acquisition cost |
| WHO | World Health Organization |
| WHO-DD | World Health Organization Drug Dictionary |
| WMD | Weighted mean difference |
| WOCBP | Women of childbearing potential |
| WPAI | Work Productivity and Activity Impairment (instrument) |
| WPL | Work productivity loss |
| XR | Extended release |

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
